Pancreatic Cancer: New Hopes for Treatment
- MedReport Foundation
- 2 hours ago
- 4 min read
Pancreatic cancer is a lethal cancer that stands as the sixth leading cause of cancer-related
deaths worldwide. Despite advances in medicine, its five-year survival rate remains
approximately 10%, largely due to diagnoses at late-stages and the lack of effective screening strategies (1).
Even when detected, pancreatic cancer is difficult to treat. As result, researchers are working hard to develop more effective treatments that can improve patient outcomes.
Current Treatment Options
Treatment for pancreatic cancer largely depends on how advanced the disease is at diagnosis. Standard treatment options include surgery, chemotherapy and chemoradiotherapy (3).
Surgery offers the best chance for long-term survival. However, more than 85% of people are
diagnosed at advanced stages of disease, when the tumour can no longer be safely or
completely removed. In these cases, chemotherapy and radiation therapy are used to slow
disease progressions and relieve symptoms. However, these treatments are not always
effective (3, 4).
Why is Pancreatic Cancer So Difficult to Treat?
Pancreatic cancer is challenging to treat for several reasons. One major issue is that early
symptoms are often mild or non-specific, meaning the cancer is usually detected only after it
has progressed to stages where surgery is no longer possible (6).
Another important factor is resistance to treatment. Many pancreatic tumours are driven by
mutations in the KRAS gene, which contribute to therapeutic resistance. Furthermore, the
tumour environment can limit how well drugs reach cancer cells, further reducing treatment
success (4).
Together, these challenges highlight the need for more targeted and innovative approaches,
such as therapies that directly target KRAS mutations and newer strategies like mRNA
vaccines.
New and Emerging Treatments
KRAS Inhibitors
One of the most promising new approaches focuses on targeting mutations in the KRAS
gene, which are found in over 90% of pancreatic cancers. These mutations drive cancer
growth by activating pathways that allow tumour cells to survive and multiple (4).
A new drug called Daraxonrasib has been developed to target KRAS more effectively. In
early clinical studies involving patients with pancreatic cancer, the drug showed promising
results, with tumours shrinking and disease control in a subset of patients.
Researchers also observed reductions in circulating tumour DNA (ctDNA), a marker of
cancer activity in the blood, suggesting that the treatment was actively targeting cancer cells
(7).
Although still in development, these findings suggest that KRAS-targeted therapies may offer
a promising new treatment in the future.
mRNA vaccines
Another emerging strategy is the use of mRNA vaccines to treat cancer. These therapies are
designed to train the immune system to recognise and attack cancer cells based on specific
mutations within a patient’s tumour (4).
One example is a personalised mRNA vaccine called Autogene Cevumeran, which is tailored
to the individual genetic profile of a patient’s cancer. In early clinical trials, this approach
triggered an immune response in a proportion of patients, with some showing long-lasting
immune responses against their tumours. These responses were associated with delayed
disease recurrence in certain patients (8).
While still in early stages of development, mRNA vaccines represent a promising new
direction in pancreatic cancer treatment, particularly as apart of combination therapies.
Conclusion
Although pancreatic cancer remains difficult to treat, ongoing research is beginning to change how the disease is approached. New strategies, such as KRAS-targeted therapies and mRNA vaccines, offer promising alternatives to traditional treatments. While these approaches are still in development, they represent an important step toward more effective and personalised care.
References:
1. Leiphrakpam PD, Chowdhury S, Zhang M, Bajaj V, Dhir M, Are C. Trends in the Global
Incidence of Pancreatic Cancer and a Brief Review of its Histologic and Molecular
Subtypes. Journal of Gastrointestinal Cancer [Internet]. 2025 Feb 24 [cited 2026 Apr
13];56(1). Available from: https://pubmed.ncbi.nlm.nih.gov/39992560/
2. John Hopkins Medicine. Pancreas Basics - Pancreatic Cancer | Johns Hopkins Pathology
[Internet]. pathology.jhu.edu. 2022. Available from:
https://pathology.jhu.edu/pancreas/basics (Source for comparative figure)
3. Overcoming therapy resistance in pancreatic cancer: New insights and future directions.
Biochemical Pharmacology [Internet]. 2024 Nov [cited 2026 Apr 13];229:116492.
4. Rozengurt E, Eibl G. Pancreatic cancer: molecular pathogenesis and emerging therapeutic
strategies. Signal Transduction and Targeted Therapy [Internet]. 2026 Jan 3 [cited 2026
Apr 13];11(1). Available from: https://www.nature.com/articles/s41392-025-02499-y
5. How Is The Extent Of Pancreatic Cancer Assessed (staging)? - Pancreatica.org [Internet].
Pancreatica.org. 2022 [cited 2026 Apr 13]. Available from: https://pancreatica.org/how-
is-the-extent-of-pancreatic-cancer-assessed-staging/ (Source for comparative figure)
6. Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C, Yang H. Chemoresistance in
Pancreatic Cancer. International Journal of Molecular Sciences [Internet]. 2019 Sept 11
[cited 2026 Apr 13];20(18):4504. Available from:
7. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase
1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with
RAS mutant pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology
[Internet]. 2025 [cited 2026 Apr 13];. Available from:
8. Lopez J, Powles T, Braiteh F, Siu LL, LoRusso P, Friedman CF, et al. Autogene
cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nature
Medicine [Internet]. 2025 Jan [cited 2026 Apr 13];31(1):152–64. Available from:
